glp-1 shortage The promise and peril of agonists: What we do (and don't) know as of August 2024 GLP-1 shortage exposed a bigger

In 2018, another non-peptide candidate for the inhibition of the GIP receptor was presented using an antibody-based approach

It is unknown whether Ozempic causes thyroid C-cell tumors in humans

An important feature of GLP-1 RA use in type 2 diabetes is weight loss, which reduces insulin resistance and typically reaches a plateau after around 6 months of treatment

Fundoscopy included assessment of absence or presence of papilledema and secondary optic atrophy

On August 1, 2024, North Carolina Medicaid launched coverage for glucagon-like peptide 1 (GLP-1s) drugs for weight loss despite the State Health Plan (SHP) ending coverage on April 1, 2024